Either TSC1 or TSC2 variants can inactivate the TSC1/TSC2 complex, which results in the hyperactivation of the mTOR pathway and promotes cell growth and proliferation, leading to the development of benign tumors or hamartomas in multiple organ systems, including the skin, brain, eyes, heart, and kidneys. This evidence concerns the gene TSC1 and benign neoplasm.